

# The ACC Decision Pathway

Is the patient  $\geq 18$  years old and have all of the following?

- T2DM
- Established ASCVD

No

Insufficient evidence to recommend SGLT2 inhibitor or GLP-1 RA for ASCVD risk reduction

Yes

Do any of the following apply to the patient?

- ESRD
- Ongoing pregnancy
- Currently breastfeeding

No

Consider the timing of starting a SGLT2 inhibitor or GLP-1 RA

- In patient discharged following hospitalization for ASCVD- or T2DM-related event
- In patient with T2DM or ASCVD newly diagnosed with the other condition
- In patient with T2DM and ASCVD

Yes

Do not start SGLT2 inhibitor or GLP-1 RA at this time

Initiate discussion incorporating patient and clinician preference and priorities

Patient does not wish to start SGLT2 inhibitor or GLP-1 RA at this time.

GLP-1 RA is selected

Start GLP-1 RA

- Liraglutide is currently preferred
- Uptitrate slowly to avoid nausea
- Adjust other antihyperglycemic agents as indicated

Monitor response to therapy

SGLT2 inhibitor is selected

Start SGLT2 inhibitor

- Empagliflozin is currently preferred
- No uptitration required
- Adjust other antihyperglycemic agents as indicated

Monitor response to therapy